INmune Bio, Inc. (NASDAQ:INMB) Shares Purchased by Millennium Management LLC

Millennium Management LLC increased its position in shares of INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 43.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 291,327 shares of the company's stock after acquiring an additional 88,823 shares during the quarter. Millennium Management LLC owned about 1.31% of INmune Bio worth $1,360,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of INMB. Raymond James Financial Inc. purchased a new stake in INmune Bio during the 4th quarter worth approximately $2,221,000. Dauntless Investment Group LLC purchased a new stake in INmune Bio during the 4th quarter worth approximately $896,000. Renaissance Technologies LLC grew its position in INmune Bio by 73.3% during the 4th quarter. Renaissance Technologies LLC now owns 185,800 shares of the company's stock worth $868,000 after purchasing an additional 78,600 shares during the last quarter. Walleye Capital LLC purchased a new stake in INmune Bio during the 4th quarter worth approximately $157,000. Finally, BNP Paribas Financial Markets grew its position in INmune Bio by 799.9% during the 4th quarter. BNP Paribas Financial Markets now owns 25,513 shares of the company's stock worth $119,000 after purchasing an additional 22,678 shares during the last quarter. Hedge funds and other institutional investors own 12.72% of the company's stock.

Analyst Ratings Changes

Several research firms have weighed in on INMB. Maxim Group boosted their target price on shares of INmune Bio from $22.00 to $30.00 and gave the stock a "buy" rating in a research report on Thursday, February 13th. Scotiabank boosted their target price on shares of INmune Bio from $22.00 to $23.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, February 11th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $22.80.

INmune Bio Trading Up 3.7%

Shares of INMB stock traded up $0.27 during trading hours on Friday, hitting $7.62. The company's stock had a trading volume of 427,639 shares, compared to its average volume of 273,998. The company has a 50 day moving average of $7.49 and a 200 day moving average of $7.12. The stock has a market cap of $175.14 million, a PE ratio of -3.50 and a beta of 1.55. INmune Bio, Inc. has a 12-month low of $4.32 and a 12-month high of $10.50.

INmune Bio (NASDAQ:INMB - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). The business had revenue of $0.05 million during the quarter. As a group, analysts anticipate that INmune Bio, Inc. will post -2.24 earnings per share for the current fiscal year.

INmune Bio Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.